LEWISBERRY, Pa., Feb. 12 /PRNewswire-FirstCall/ -- Unilife Corporation (Company) today announced that the US Securities and Exchange Commission (SEC) declared the Company's Form 10 registration statement effective, clearing the path for Unilife Corporation's listing on the NASDAQ.
The Company expects trading of Unilife Corporation common stock to commence on NASDAQ on or around February 16, 2010 under the ticker "UNIS".
Alan Shortall, CEO of Unilife, stated, "I would like to thank the Unilife team for the completion of this significant corporate milestone. In particular, I wish to note the important contribution made by the Unilife Finance department, and our Australian and US legal representatives, DLA Phillips Fox and DLA Piper who worked tirelessly to achieve this approval within our projected timeframe.
"Despite severe weather conditions in the eastern portion of the US that caused a shutdown of all Federal Government offices in Washington, DC, and restricted operations in both Pennsylvania and New York City, our team has been able to work co-operatively to complete the work necessary to achieve this result. I must compliment the Unilife team and our advisors for an outstanding effort."
The Company also wishes to advise that by the time trading of Unilife common stock commences on NASDAQ, it will have published on its website (http://www.unilife.com/) a list of Frequently Asked Questions (FAQs) to support shareholders wishing to trade on either the ASX or NASDAQ. The Company has also now opened an Investor Hotline to assist with shareholder enquiries during this period. The enquiry line numbers are 1800 632 680 (Australia toll free), +1 866 496 5819 (US toll free) and or +61 2 8256 3394 (International).
About Unilife Corporation
Unilife Corporation are a US based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife is ISO 13485 certified and has FDA-registered medical device manufacturing facilities in Pennsylvania.
Unilife's main product is the Unifill(TM) ready-to-fill syringe, which is designed to be supplied to pharmaceutical manufacturers in a form that is ready for filling with injectable drugs and vaccines. The Company has a strategic partnership with sanofi-aventis, who has the exclusive right to negotiate for the purchase of the Unifill(TM) syringe and is funding an industrialization program for the product. In addition, Unilife has retained the right to negotiate with other pharmaceutical companies seeking to utilize the Unifill syringe with drugs and vaccines marketed in therapeutic areas outside of those secured exclusively by sanofi-aventis.
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our registration statement on Form 10 and those described from time to time in our future reports which we will file with the Securities and Exchange Commission.
Investor Contacts (US): Todd Fromer / Garth Russell KCSA Strategic Communications + 1 212-682-6300
Unilife Corporation
CONTACT: Todd Fromer or Garth Russell, both of KCSA Strategic
Communications, +1-212-682-6300
Web Site: http://www.unilife.com/
